Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 51Head & Neck 9Gastrointestinal 9Tumor-Agnostic 6Gynecologic 6Other solid neoplasm 4Endocrine 3Thoracic 2Sarcoma 2Genitourinary 2Dermatologic 2Plasma cell 1CNS 1

Conditions

Melanoma 2Uveal Melanoma 1Breast Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Alpelisib × Dermatologic × Clear all
NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

M.D. Anderson Cancer Center

Phase 1 Recruiting
50 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT02273219 2023-08-15

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Columbia University

Phase 1 Completed
30 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡